entity

sess_sda-2026-04-01-gap-006

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about sess_sda-2026-04-01-gap-006: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2Connections

0Hypotheses

3Analyses

2Outgoing

0Incoming

0Experiments

4Debates

No AI portrait yet

Outgoing (2)

Target	Relation	Type	Str
processed	causal_extracted	sentinel	0.00
processed	causal_extracted	sentinel	0.00

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (3)

Scientific analyses that reference this entity

What are the specific design principles for small molecules that can selectively

medicinal chemistry | 2026-04-10 | 0 hypotheses

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.738

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (4)

Multi-agent debates referencing this entity

The debate identified that TDP-43 undergoes both normal and pathological phase s

closed · Rounds: 4 · Score: 0.43 · 2026-04-21

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

TDP-43 phase separation therapeutics for ALS-FTD

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

What are the mechanisms underlying tdp-43 phase separation therapeutics for als-

closed · Rounds: 4 · Score: 0.95 · 2026-04-01

Related Research

Hypotheses and analyses mentioning sess_sda-2026-04-01-gap-006 in their description or question text

No additional research found